Elocta (Efmoroctocog alfa Vials) 500 IE

Elocta (Efmoroctocog alfa) 500 IE vials are a factor VIII replacement therapy for hemophilia A. This injectable treatment helps manage and prevent bleeding episodes. Store between 2-8°C to maintain potency. Always follow healthcare provider guidance when using this medication.

Strength

500 IE

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Swedish Orphan Biovitrum

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Elocta is used to treat and prevent bleeding in patients with hemophilia A, a genetic disorder causing insufficient clotting factor VIII. It replaces the missing clotting protein to help blood clot normally. This medication is prescribed for routine prophylaxis or on-demand treatment of bleeding episodes. People often ask what is efmoroctocog alfa used for and how it helps with hemophilia management.

Side Effects

Elocta works by temporarily increasing factor VIII levels in the bloodstream to support proper clotting. Users may notice improved bleeding control and fewer spontaneous bleeds with regular use. Some patients report feeling more active when their clotting function is stabilized. The effects vary based on individual treatment plans and adherence.

Precautions & Warnings

Keep Elocta vials refrigerated between 2-8°C and protect from light. Do not freeze or shake the vial. Always inspect the solution for particles or discoloration before use. Follow proper reconstitution and injection techniques as directed by your healthcare professional. Dispose of used needles and vials safely in a sharps container.

Avoid Interactions

Elocta may interact with other medications that affect blood clotting, including anticoagulants and platelet aggregation inhibitors. Some antibiotics and chemotherapy drugs could potentially alter its effectiveness. Always inform your healthcare provider about all medications you're taking before starting Elocta therapy. Blood tests may be needed to monitor clotting function during treatment.

Frequently Asked Questions

Efmoroctocog alfa is used to treat and prevent bleeding episodes in patients with hemophilia A by replacing missing clotting factor VIII.

Elocta vials should be stored refrigerated between 2-8°C and protected from light. Do not freeze or shake the vial.

Elocta is available by prescription only. Consult your healthcare provider for proper evaluation before purchasing any factor replacement therapy.

Some users may experience headache, nausea, or injection site reactions. Always report any unusual symptoms to your healthcare provider.

Dosage frequency depends on individual treatment plans. Some patients receive doses every few days while others may have different schedules.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.